Kurser indlæses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Bumrungrad Hospital Q1 2026: earnings and revenue expectations exceeded, stock falls premarket
Bumrungrad Hospital reported Q1 2026 EPS of $2.06 versus a $2.04 estimate and revenue of $6.2 billion (expectation $5.98 billion). EBITDA rose 5% and revenue from non-Thai patients increased 4.2%, while revenue from Thailand fell 3.6%. The share price fell 2.86% premarket to $170, pressured by declining domestic sales and longer receivable days (71.7 days). Management does not plan further price increases and is focusing on international expansion and growing outpatient and robot-assisted services. » Mere på de.investing.com
Bumrungrad Hospital beats Q1 forecasts, stock falls nonetheless
Bumrungrad Hospital reported Q1 2026 earnings per share of $2.06 (expectation $2.04) and revenue of $6.2 billion (forecast $5.98 billion). The EBITDA margin rose to a record high of 39.3%, driven by growth in non‑Thai patients, notably from the Middle East. Despite the stronger metrics, the share price fell 2.86% in premarket trading. The company plans capacity expansions (Phuket project, » Mere på de.investing.com
Bumrungrad Hospital PCL posts record EBITDA margin despite revenue decline
Bumrungrad Hospital PCL reported Q2 2025 revenue down 3.6% to THB 6,104 million, EBITDA of THB 2,537 million (-1.6%), and a record EBITDA margin of 41.6%; net profit fell 3.8% to THB 1,858 million with a near-stable net margin of 30.4%. The share of international patients dropped to 64%, international revenue declined 6.6%, while Middle East revenue rose sequentially versus Q1 (UAE +46%, Saudi Arabia +54%, Oman +28%). The company has a strong net cash position, is investing in robotics and specialty centers, and paid THB 2 per share in the first half with a 44% payout ratio. » Mere på de.investing.com
Bumrungrad Hospital achieves record EBITDA margin despite revenue decline in Q2 2025
Bumrungrad Hospital reported a 3.6% decrease in revenue for the second quarter of 2025, but achieved a record EBITDA margin of 41.6% thanks to effective cost control. The net profit margin remained stable, and the company increased its dividend payout while advancing strategic investments such as the planned cancer center and the expansion of robotic surgery. The Middle East market showed a strong recovery, while challenges persisted in other regions such as China. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 163,77 mio. | 3,95 % |
| Bruttofortjeneste | 85,23 mio. | 3,12 % |
| Nettoresultat | 49,65 mio. | 2,20 % |
| EBITDA | 67,09 mio. | 0,94 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 4,33 mia. € |
Antal aktier | 794,97 mio. |
Højeste/laveste i 52 uger | 5,45 € - 4,41 € |
Udbytteafkast | 6,65 % |
Udbytte TTM | 0,34 € |
Beta | 0,18 |
P/E (PE Ratio) | 20,08 |
PEG (PEG Ratio) | 9,90 |
K/I (PB Ratio) | 5,64 |
P/S (PS Ratio) | 5,99 |
Virksomhedsprofil
Bumrungrad Hospital Public Company Limited ejer og driver sundhedsrelaterede virksomheder i Thailand og internationalt. Virksomheden tilbyder diagnostiske, terapeutiske og intensivbehandlingsfaciliteter i et medicinsk center. Dens ambulante klinikker/centre omfatter allergi, arytmi, adfærdsmæssig sundhed, amning, brystpleje, børn, tandpleje, diabetes, diagnostik, dialyse, fordøjelsessygdomme, akutmodtagelse, øjne, fertilitet og IVF, sundhedsscreening, hørelse og balance, hjerteklapper, kræft, hyperbar iltbehandling, hypertension, ledudskiftning, lever, hukommelse, mænd, nefrologi, neurovidenskab, new life healthy aging, ortopædi, Parkinsons sygdom og bevægelsesforstyrrelser, perinatal, fysioterapi og rehabilitering, plastikkirurgi, lunger, refraktiv kirurgi, robotassisteret skoliose- og kirurgi, hud, søvnlaboratorium, rygsøjle, sportsmedicin og livsstil, kirurgi, rejsemedicin, urologi, vitalife og kvinder samt øre-, næse- og halscentre. Derudover er virksomheden involveret i aktiviteter med holding af fast ejendom, levering af kliniske forskningsydelser, distribution af farmaceutiske og medicinske varer i specialbutikker, drift af et center for personaleudvikling og uddannelse inden for sundhedsydelser samt forretning med henvisningsservice for patienter. Virksomheden driver 580 senge og ca. 56 klinikker/centre. Virksomheden blev grundlagt i 1980 og har hovedsæde i Bangkok, Thailand.
| Navn | Bumrungrad Hospital PCL |
| CEO | Artirat Charukitpipat |
| Hjemsted | Bangkok,
bm Thailand |
| Websted | |
| Børsnotering | 31.12.2007 |
| Medarbejdere | 4.506 |
Tickersymboler
| Børs | Symbol |
|---|---|
XETRA | BZ7A.F |
Pnk | BUHPF |
München | BZ7A.MU |